UCB Pharmaceuticals SWOT Analysis, Competitors, Segmentation, Target Market, Positioning & USP

UCB Pharmaceuticals

Pharmaceutical

Pharma and Healthcare

Aspiring to be patient centric biopharma leader

It is global biopharma focused on severe diseases with operations in over 40 countries

Central nervous system diseases & immunology

Healthcare professionals offering solutions to patients suffering from severe diseases

A global biopharma focused in severe diseases focused in two areas namely CNS & immunology

Below are the Strengths in the SWOT Analysis of UCB Pharmaceuticals:

1. UCB has nearly 9000 well trained employees

2. Strong global presence in over 40 countries

3. It has strong product pipeline with many molecules in last stages of development especially in case of CNS

4. They have four major blockbuster products such as Cimzia, Vimpat, Neutro, Keppra.

Here are the weaknesses in the UCB Pharmaceuticals SWOT Analysis:

1. Company operates in limited segments of medication for severe diseases only

2. It has limited presence in developing world as majority of revenue comes from America & Europe operations

Following are the Opportunities in UCB Pharmaceuticals SWOT Analysis:

1. There is good scope for development of new treatment options in epilepsy

2.  they can further utilize full potential of their blockbuster drugs

3. Increasing awareness about severe diseases

The threats in the SWOT Analysis of UCB Pharmaceuticals are as mentioned:

1. Economic instability of euro zone can hurt revenue of company

2. Strong FDA drug development guidelines

3. Increasing competition of other pharma majors in their business segments

Below are the top 4 UCB Pharmaceuticals competitors:

1. Abbott laboratories
2. Amgen

3. AstraZeneca

4. Forest laboratories